Receptor Life Sciences

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, recently announced it’s expanding the potential clinical utility of RLS103, a dry powder inhaled cannabidiol (CBD)​​​​​​ into epilepsy treatment. Dry...

The FDA accepted Receptor Life Sciences’ investigational new drug application for RLS103. RLS103, a dry powder inhaled CBD, which is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder. RLS103 uses a drug delivery technology comprising a...